McAinsh J, Cruickshank J M
Imperial Chemical Industries PLC, ICI Pharmaceuticals, Macclesfield, Cheshire, U.K.
Pharmacol Ther. 1990;46(2):163-97. doi: 10.1016/0163-7258(90)90092-g.
Beta-adrenergic blocking drugs are a widely used, well tolerated and effective treatment for a variety of cardiovascular and noncardiovascular disorders. Over the years, beta-blockers have been associated with an incidence, albeit low, of CNS side effects. The question of interest, however, is whether the incidence is the same for all members of the class or whether other properties, such as hydrophilicity, have a bearing on the incidence of this type of side effect? This article addresses this question. In pharmacokinetic terms the lipophilic beta-blockers have been shown, both in animals and man, to readily cross the blood-brain barrier in contrast to hydrophilic beta-blockers. This is thought to have possible clinical relevance with respect to the relative incidence of CNS side-effects. To clarify the situation every published clinical paper, in which the beta-blockers propranolol (highly lipophilic, nonselective, no intrinsic sympathomimetic activity (ISA)), pindolol (moderately lipophilic, nonselective, moderate ISA), metoprolol (moderately lipophilic, beta 1-selective, no ISA) and atenolol (hydrophilic beta 1-selective, no ISA) were compared, was assessed for information pertaining to CNS side effects. This comprehensive review of the literature has shown, with few exceptions, that the incidence of CNS side effects such as sleep disturbances, dreaming, nightmares and hallucinations following clinically accepted doses of the four beta-blockers under scrutiny is generally low and that effects on short-term memory are minimal or absent. However, within this group of four drugs the incidence of these side effects is lowest with hydrophilic atenolol and generally highest with pindolol and propranolol. Metoprolol occupies an intermediate position. This order is in agreement with the pharmacokinetic observation that the more hydrophilic the molecule, the less is found in the brain tissue of both animals and man, although in the case of pindolol other factors may be important. The clinical relevance of studies involving psychometric testing is not clear.
β-肾上腺素能阻滞剂是一种广泛应用、耐受性良好且对多种心血管和非心血管疾病有效的治疗药物。多年来,β受体阻滞剂与中枢神经系统副作用的发生率相关,尽管发生率较低。然而,人们感兴趣的问题是,这类药物的所有成员的发生率是否相同,或者其他特性,如亲水性,是否与这类副作用的发生率有关?本文探讨了这个问题。从药代动力学角度来看,与亲水性β受体阻滞剂相比,无论是在动物还是人类中,脂溶性β受体阻滞剂都已被证明能够轻易穿过血脑屏障。这被认为与中枢神经系统副作用的相对发生率可能具有临床相关性。为了澄清这种情况,对每一篇已发表的临床论文进行了评估,这些论文比较了β受体阻滞剂普萘洛尔(高度脂溶性、非选择性、无内在拟交感活性(ISA))、吲哚洛尔(中度脂溶性、非选择性、中度ISA)、美托洛尔(中度脂溶性、β1选择性、无ISA)和阿替洛尔(亲水性β1选择性、无ISA),以获取与中枢神经系统副作用相关的信息。对文献的全面回顾表明,除了少数例外,在接受临床认可剂量的四种受审查β受体阻滞剂后,中枢神经系统副作用如睡眠障碍、多梦、噩梦和幻觉的发生率通常较低,对短期记忆的影响最小或不存在。然而,在这四种药物中,这些副作用的发生率在亲水性阿替洛尔中最低,在吲哚洛尔和普萘洛尔中通常最高。美托洛尔处于中间位置。这个顺序与药代动力学观察结果一致,即分子越亲水,在动物和人类脑组织中发现的就越少,尽管就吲哚洛尔而言,其他因素可能也很重要。涉及心理测量测试的研究的临床相关性尚不清楚。